new glp 1 receptor agonists Trends in the Development of GLP-1 Understanding GLP-1 receptor agonists and

Berberine (BBR) exhibits significant anti-diabetic effects by enhancing insulin sensitivity, promoting glycolysis, and inhibiting gluconeogenesis

Fahima Azizi & Dr

Beyond these frontrunners, the pipeline is expanding: Novo Nordisk filed for FDA approval of CagriSema in 2025, the first once-weekly combination of GLP1 and amylin analogue

2) Of the weight lost, what proportion came from lean or muscle-related compartments

Rhode Island's Medicaid agency proposes ending GLP-1 coverage for weight loss while keeping diabetes uses, citing soaring costs.

Clinical Frameworks: Defining Obesity Beyond Body Mass Index (BMI) An important milestone of 2025 was the publication of The Lancet Diabetes & Endocrinology Commission on the Definition and Diagnostic Criteria of Clinical Obesity